On 20 January 2009, orphan designation (EU/3/08/604) was granted by the European Commission to Adienne S.r.l., Italy, for recombinant human minibody against complement component C5 fused with RGD-motif for the prevention of the ischaemia/reperfusion injury associated with solid organ transplantation.
In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2019 on request of the Sponsor.
EU/3/08/604: Public summary of positive opinion for orphan designation of recombinant human minibody against complement component C5 fused with RGD-motif for prevention of the ischaemia/reperfusion injury associated with... (PDF/154.18 KB)
First published: 29/06/2009
Last updated: 22/01/2014
Recombinant human minibody against complement component C5 fused with RGD-motif
|Disease / condition||
Prevention of the ischaemia/reperfusion injury associated with solid organ transplantation
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;